Register Login

PURPLE BIOTECH LTD. (PPBT)

SymbolPPBT
NamePURPLE BIOTECH LTD.
SectorHEALTH CARE
RegionMiddle East
IndustryPharmaceutical Preparations
Address4 OPPENHEIMER STREET, REHOVOT, L3 7670104
Telephone97239333121
Fax03-5097196
Emailir@purple-biotech.com
Websitehttps://www.purple-biotech.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ;TASE
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001614744
Description

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Additional info from NASDAQ:
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

2026-08-14 15:02

New Form SCHEDULE 13G/A - PURPLE BIOTECH LTD. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001446580-26-000101 <b>Size:</b> 13 KB

Read more
2026-08-10 20:06

Other Report or Announcement

Read more
2026-08-07 11:05

FORM 6-K -Second Quarter 2026 Financial Results

Read more
2026-08-07 11:00

Purple Biotech Reports Second Quarter 2026 Financial Results

Read more
2026-07-29 20:18

Other Report or Announcement

Read more
2026-06-23 14:02

Presentation-June 2026

Read more
2026-06-11 11:20

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240s AntiTumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Read more
2026-06-11 11:00

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240s Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Read more
2026-05-20 18:29

New Form F-3 - PURPLE BIOTECH LTD. <b>Filed:</b> 2026-05-20 <b>AccNo:</b> 0001213900-26-059665 <b>Size:</b> 874 KB

Read more
2026-05-15 11:04

Other Report or Announcement

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06919666 NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic H… Phase1 Head and Neck Cancer Active_Not_Recruiting 2025-06-12 2031-02-01 ClinicalTrials.gov
Total clinical trials: 1
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
NT219 Other Phase PHASE1 Head and Neck Cancer ACTIVE_NOT_RECRUITING NCT06919666
NT219 Other Phase PHASE1 Head and Neck Cancer ACTIVE_NOT_RECRUITING NCT06919666
NT219 Other Phase PHASE1 Head and Neck Cancer ACTIVE_NOT_RECRUITING NCT06919666
NT219 DRUG Phase PHASE1 Head and Neck Cancer ACTIVE_NOT_RECRUITING NCT06919666
Total products: 4